CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
Cancer Treatment Reviews · 2025-12 · 141 · 103046
DOI: 10.1016/j.ctrv.2025.103046 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-12. Verfasst von Reza Elahi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy has transformed cancer immunotherapy, achieving durable complete remissions in hematologic cancers. Yet its translation to solid tumors like hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide, faces formidable barriers, including immunosuppressive tumor microenvironments (TMEs), antigen heterogeneity, and risks of on-target/off-tumor toxicity. This review discusses the evolving role of CAR-T therapy in HCC across three domains: (1) foundational concepts in CAR-T design, mechanistic action, and antigen-targeting strategies; (2) breakthroughs from preclinical studies and early-phase clinical trials, such as glypican-3 (GPC3) and alpha-fetoprotein (AFP) directed CAR-T cells that have demonstrated preliminary safety and anti-tumor activity; and (3) innovative strategies to overcome TME-driven resistance, including metabolic reprogramming and stromal modulation. We highlight cutting-edge engineering solutions such as armored CAR-T cells engineered for cytokine support, dual-targeting constructs to mitigate antigen escape, and hypoxia-resistant designs alongside synergistic approaches combining CAR-T with immune checkpoint inhibitors or tyrosine kinase inhibitors. Furthermore, we dissect emerging tactics to disrupt TME immunosuppression. While CAR-T therapy holds promise for redefining HCC management, its success will depend on overcoming biological and logistical barriers through patient-tailored designs and robust translational pipelines. Future directions should prioritize biomarker-driven clinical trials, scalable manufacturing platforms, and integration with existing multimodal HCC therapies to maximize durable responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA.
- Department of internal medicine, Maimonides medical center, Brooklyn, NY 11219, USA.
- Division of Hematology & Oncology, Department of Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA. Electronic address: saeeda3@upmc.edu.
Zitieren
APA
Elahi, R., Alami Idrissi, Y., & Saeed, A. (2025). CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews, 141, 103046. https://doi.org/10.1016/j.ctrv.2025.103046
Vancouver
Elahi R, Alami Idrissi Y, Saeed A. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation. Cancer Treatment Reviews. 2025;141:103046. doi:10.1016/j.ctrv.2025.103046
BibTeX
@article{Elahi2025,
author = {Elahi, Reza and Alami Idrissi, Yassine and Saeed, Anwaar},
title = {CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation},
journal = {Cancer Treatment Reviews},
year = {2025},
volume = {141},
pages = {103046},
doi = {10.1016/j.ctrv.2025.103046}
}
EUVIMED